3/2
09:27 am
gmab
Genmab A/S (GMAB) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
Genmab A/S (GMAB) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $40.00 price target on the stock.
3/2
09:12 am
gmab
Transactions in Connection with Share Buy-back Program [Yahoo! Finance]
Low
Report
Transactions in Connection with Share Buy-back Program [Yahoo! Finance]
2/28
07:02 pm
gmab
Is Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Is Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price Weakness [Yahoo! Finance]
2/28
07:38 am
gmab
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]
2/27
03:34 pm
gmab
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab [Yahoo! Finance]
2/25
11:04 am
gmab
Genmab to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Genmab to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/24
03:40 pm
gmab
Capital Increase in Genmab as a Result of Employee Warrant Exercise [Yahoo! Finance]
Low
Report
Capital Increase in Genmab as a Result of Employee Warrant Exercise [Yahoo! Finance]
2/23
12:39 pm
gmab
Genmab A/S (NASDAQ:GMAB) had its price target lowered by analysts at Guggenheim from $45.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its price target lowered by analysts at Guggenheim from $45.00 to $40.00. They now have a "buy" rating on the stock.
2/21
05:42 am
gmab
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales [Yahoo! Finance]
Low
Report
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales [Yahoo! Finance]
2/20
10:39 am
gmab
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons [Yahoo! Finance]
Low
Report
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons [Yahoo! Finance]
2/20
09:34 am
gmab
Novo Nordisk nominates three new board directors, two with pharma experience [Seeking Alpha]
Low
Report
Novo Nordisk nominates three new board directors, two with pharma experience [Seeking Alpha]
2/18
09:22 am
gmab
Notice to Convene the Annual General Meeting of Genmab A/S [Yahoo! Finance]
Low
Report
Notice to Convene the Annual General Meeting of Genmab A/S [Yahoo! Finance]
2/18
08:13 am
gmab
Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $39.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $39.00 to $40.00. They now have a "buy" rating on the stock.
2/17
04:16 pm
gmab
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/17
11:01 am
gmab
Genmab Publishes 2025 Annual Report
Low
Report
Genmab Publishes 2025 Annual Report
2/17
08:42 am
gmab
Genmab A/S (NASDAQ:GMAB) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.50 price target on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.50 price target on the stock.
2/17
01:18 am
gmab
AbbVie: Dominating Immunology While Building Oncology Upside [Seeking Alpha]
Low
Report
AbbVie: Dominating Immunology While Building Oncology Upside [Seeking Alpha]
2/16
08:05 am
gmab
Genmab A/S (NASDAQ:GMAB) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
2/11
03:10 pm
gmab
Where is Genmab A/S (GMAB) Headed According to Wall Street? [Yahoo! Finance]
Low
Report
Where is Genmab A/S (GMAB) Headed According to Wall Street? [Yahoo! Finance]
2/11
06:32 am
gmab
Is Genmab (CPSE:GMAB) Attractively Priced After Recent Share Price Pullback? [Yahoo! Finance]
Low
Report
Is Genmab (CPSE:GMAB) Attractively Priced After Recent Share Price Pullback? [Yahoo! Finance]
1/30
02:18 am
gmab
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]
Low
Report
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]
1/29
04:27 pm
gmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
1/28
08:46 am
gmab
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
1/24
07:11 pm
gmab
Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum [Yahoo! Finance]
Low
Report
Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum [Yahoo! Finance]
1/23
10:06 am
gmab
Genmab: Darzalex Growth Fuels Rally, Upside Is Tight [Seeking Alpha]
Low
Report
Genmab: Darzalex Growth Fuels Rally, Upside Is Tight [Seeking Alpha]